Evidence map›Paper›PMID 40421176›Full record

ArticleJournal of mass spectrometry and advances in the clinical lab2025

Validation of an LC-MS/MS method for urinary homovanillic and vanillylmandelic ACIDS and application to the diagnosis of neuroblastoma.

Lucilla Rossi, Yvette A H Matser, Sebastiano Barco, Alessia Cafaro, Federica Pigliasco, Margherita Biondi, Fabrizio Mancin, Maria van der Ham, Monique G M de Sain-van der Velden, Shifra Ash and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of mass spectrometry and advances in the clinical lab, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Lucilla RossiBiochemistry, Pharmacology and Newborn Screening Unit, Central Laboratory of Analysis, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Yvette A H MatserPrincess Máxima Center for Paediatric Oncology, Utrecht, The Netherlands.
Sebastiano BarcoBiochemistry, Pharmacology and Newborn Screening Unit, Central Laboratory of Analysis, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Alessia CafaroBiochemistry, Pharmacology and Newborn Screening Unit, Central Laboratory of Analysis, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Federica PigliascoBiochemistry, Pharmacology and Newborn Screening Unit, Central Laboratory of Analysis, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Margherita BiondiBiochemistry, Pharmacology and Newborn Screening Unit, Central Laboratory of Analysis, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Fabrizio MancinDepartment of Chemical Sciences - DiSC, University of Padua, Padua, Italy.
Maria van der HamDepartment of Genetics, Section Metabolic Diagnostics, Wilhelmina Children's Hospital, Utrecht, The Netherlands.
Monique G M de Sain-van der VeldenDepartment of Genetics, Section Metabolic Diagnostics, Wilhelmina Children's Hospital, Utrecht, The Netherlands.
Shifra AshRuth Rappaport Children's Hospital, Haifa, Israel.
Maja Beck PopovicUniversity Hospital Lausanne, Lausanne, Switzerland.
André B P van KuilenburgLaboratory of Genetic Metabolic Diseases, Amsterdam UMC University of Amsterdam, Amsterdam, The Netherlands.
Massimo ContePediatric Oncology and Hematology Department, IRCCS Istituto Giannina Gaslini, Genova, Italy.
Alberto GaraventaPediatric Oncology and Hematology Department, IRCCS Istituto Giannina Gaslini, Genova, Italy.
Godelieve A M TytgatPrincess Máxima Center for Paediatric Oncology, Utrecht, The Netherlands.
Giuliana CangemiBiochemistry, Pharmacology and Newborn Screening Unit, Central Laboratory of Analysis, IRCCS Istituto Giannina Gaslini, Genoa, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Urinary catecholamine metabolites are well-established biomarkers for neuroblastoma (NB). Homovanillic acid (HVA) and vanillylmandelic acid (VMA) are the most frequently measured metabolites within SIOPEN - Catecholamine Working Group laboratories. Here, we evaluated the performance of a new LC-MS/MS in vitro diagnostic (IVD) kit for HVA and VMA to facilitate inter-laboratory harmonization. Methods: HVA and VMA and their deuterated internal standards were analyzed with a commercial method, on a ThermoFisher Quantiva LC-MS/MS. Validation was performed first using internal quality control and external quality assessment (IQC and EQA) samples. Next by clinical validation on 120 samples, previously tested by HPLC-ECD. Finally, 36 samples were exchanged between SIOPEN reference laboratories and analyzed by three methods. Results: Using QCs and EQA the method was validated in a wide calibration range (4.61-830 µmol/L for HVA and 4.44-800 µmol/L for VMA). Intra-day CVs ( Conclusion: The LC-MS/MS IVD method could be considered a useful tool for clinical laboratories involved in the measurement of catecholamines, contributing to harmonization efforts.

Indexed as

Homovanillic acidInter-laboratory harmonizationLiquid Chromatography-tandem Mass SpectrometryNeuroblastomaPediatricsUrinary catecholamineVanillylmandelic acid

Identifiers

PMID40421176
PMCPMC12105103

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.